Dr. Agarwal's Health Care Q1 FY27: Revenue surges 26% to ₹614 Cr, PAT up 44.6%
Dr. Agarwal's Health Care reported Q1 FY27 results with Revenue from Operations at ₹614 Cr, up 26.0% YoY. PAT grew 44.6% to ₹55 Cr. The company added 18 facilities, expanding its network to 304. Over 91,000 surgeries were performed, serving 882K+ patients.
The significant financial growth and network expansion are material positive developments for the company, likely to be viewed favorably by investors.
The company reported strong year-on-year growth in revenue, EBITDA, and profit after tax, along with expansion in its facility network and a high volume of surgeries performed.
Dr. Agarwal's Health Care Limited announced its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27).
The company reported a significant 26.0% year-on-year growth in Revenue from Operations, reaching ₹614 Crore. EBITDA also saw a healthy increase of 25.2% YoY to ₹177 Crore. Profit After Tax (PAT) demonstrated robust growth, rising by 44.6% YoY to ₹55 Crore.
The operational highlights for Q1 FY27 include serving over 882,000 patients and performing more than 91,000 surgeries. The company expanded its network by adding 18 new facilities, bringing the total to 304 eye care facilities across India. Specialized surgical procedures also showed strong growth, with Femto Cataracts up 33.4% and Lenticular Procedures up 36.2% YoY.
The presentation also detailed the company's financial performance, including a 23.9% increase in Total Income to ₹620 Crore. EBITDA margins stood at 28.5% and PAT margins at 8.9% for the quarter.
The company's strategic initiatives and market position were emphasized, highlighting its status as India's largest eye care services chain with a diversified geographical footprint across 14 states and 5 Union Territories, and a presence in 9 countries. The presentation also touched upon the growing eye care industry in India and Dr. Agarwal's competitive advantages.
What to do with a filing like this
Dr. Agarwal's Health Care Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Agarwal's Health Care Limited. Read the original for the full detail.